Horizon Pharma to Acquire Raptor Pharmaceuticals

On Sept. 12, 2016, Horizon Pharma announced that it will acquire Raptor Pharmaceuticals. The companies have entered into a definitive merger agreement under which Horizon will acquire all of the issued and outstanding shares of Raptor, the companies said in a press announcement. The diluted equity value of the remaining and outstanding shares of the company is approximately $800 million. The transaction is expected to close in the fourth quarter of 2016.

This acquisition will add Procysbi delayed-release capsules and Quinsair, aerosolized form of levofloxacin, to Horizon’s portfolio. In addition, Horizon says, the acquisition of Raptor diversifies the company’s revenue with 11 medicines across three business units, orphan, rheumatology, and primary care. Raptor's previously disclosed total net sales guidance for full-year 2016 is $125 million to $135 million.

Source: Horizon Pharma